Valvular Aortic valve articles

Endocarditis infecciosa post TAVI

Infective Endocarditis After TAVI

Infective Endocarditis After TAVI

Infective endocarditis after transcatheter aortic valve implantation (TAVI) is one of the most feared complications due to its morbidity and mortality. With the expansion of TAVI into all risk groups, endocarditis might be a long-term concern. However, its long-term risk seems similar to that of endocarditis with surgically-implanted biological valves; consequently, it should not affect

Mismatch protésico en válvulas supra anulares y en válvulas intra anulares

Prosthesis Mismatch in Supra and Intra Annular valves

The self-expandable valve was associated to lower prosthesis-patient mismatch (PPM) compared against the balloon expandable valve regardless annular area, according to this study soon to be published in J Am Coll Cardiol Intv. This difference was basically driven by patients with larger body surface area (>1.83m²). Prosthesis mismatch has been associated to increased mortality after transcatheter

Trombólisis local en tromboembolismo pulmonar

Incidence and Prognosis of Heart Valve Embolization

The incidence of peri-procedural transcatheter heart valve embolization and migration (TVEM) is as low as 1%. However, it is associated with increased morbidity and mortality. Peri-procedural TVEM is one of the most feared complication given its potential to transform the procedure into a catastrophe, but little do we know about its incidence (except for a

Intentando reducir la insuficiencia renal post TAVI

Trying to Reduce Post TAVR Kidney Injury

Acute kidney injury is a common complication after transcatheter aortic valve replacement (TAVR) and is associated to increased mortality both short and long-term.  In patients undergoing percutaneous coronary intervention (PCI) forcing diuresis with controlled hydration has shown to reduce the incidence of acute kidney injury in nearly 50%. However, this has not been tested in

Reparación de la válvula tricúspide con la técnica del Mitra Clip

More Evidence on Tricuspid Valve Repair

While still lacking large-scale randomized trials, evidence is slowly building for transcatheter tricuspid valve repair. This work, presented at the TCT 2019 Congress and simultaneously published in JACC, shows that transcatheter tricuspid valve repair is not only feasible, but also likely to reduce the rates of mortality and heart failure rehospitalization compared with medical therapy alone.

TAVI en insuficiencia aórtica pura

TAVR Offers Better Quality of Life to Low Risk Patients

Courtesy of Dr. Carlos Fava. As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year.   This study looked into PARTNER 3 patient health status

Highlights TCT 2019

TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions

Highlights TCT 2019

TCT 2019 | COAPT Cost Effectiveness: Better Quality of Life and Survival Rate, but Worth It?

Courtesy of SBHCI. The COAPT showed transcatheter repair of the mitral valve using the MitraClip resulted in reduced mortality and hospitalization for cardiac failure and improved quality of life, compared against optimal medical treatment in patients with cardiac failure and moderate to severe functional mitral regurgitation. The cost-effectiveness of this procedure has not been analyzed

Highlights TCT 2019

TCT 2019 | COAPT at 3 Years: MitraClip Reached Functional Mitral Regurgitation Target

Courtesy of SBHCI. Prognosis of patients with cardiac failure who develop secondary mitral regurgitation due to dilation is uncertain.   The COAPT study was carried out in 78 centers across the US and Canada and included patients with moderate to severe mitral regurgitation (3 or 4 crossovers) symptomatic despite optimal medical treatment (OMT).  614 patients were

TCT 2019 | PARTNER 2A at 5 Years: In Intermediate-Risk Patients, TAVR Is Still Head-to-Head with Surgery

Courtesy of the SBHCI. The 2-year results of the PARTNER 2A trial showed that transcatheter aortic valve implantation has a result similar to that of surgery in patients with aortic stenosis and intermediate surgical risk. We lacked long-term data, both clinical and related to prosthesis function. Now, at TCT 2019, researchers presented the 5-year data for this

Highlights TCT 2019

TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses

Courtesy of SBHCI. The aim of this work was to assess the contemporary outcomes of mitral valve-in-valve using Sapien 3 prostheses, see the differences between trasapical and transseptal access, and establish 1-year mortality predictors. Researchers analyzed retrospectively the data from the Society of Thoracic Surgeons [STS]/American College of Cardiology TVT Registry, which included 1576 patients who had

Top